Get the Stockscreener App
0.3123
6.78%
-0.0227
Pre-market:
.34
0.0277
+8.87%
Collplant Biotechnologies Ltd stock is traded at $0.3123, with a volume of 41,889.
It is down -6.78% in the last 24 hours and down -7.36% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$0.335
Open:
$0.32
24h Volume:
41,889
Relative Volume:
0.54
Market Cap:
$5.91M
Revenue:
$389.00K
Net Income/Loss:
$-13.13M
P/E Ratio:
-0.3025
EPS:
-1.0323
Net Cash Flow:
$-11.90M
1W Performance:
-11.85%
1M Performance:
-7.36%
6M Performance:
-78.76%
1Y Performance:
-84.62%
1-Day Range:
$0.301
$0.335
1-Week Range:
$0.301
$0.365
52-Week Range:
$0.2711
$3.2324
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
0.3123 | 5.91M | 389.00K | -13.13M | -11.90M | -1.0323 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
CollPlant Biotechnologies (CLGN) completes $10.4M exempt private securities deal - Stock Titan
CollPlant Biotechnologies (CLGN) files to resell 31M shares from 2026 PIPE - Stock Titan
CollPlant Biotechnologies Ltd SEC Filing (Jul 17, 2026) - Stock Titan
Collplant Biotechnologies Ltd (CLGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CollPlant Biotechnologies files prospectus for 31.047M share offering - scanx.trade
CollPlant Biotechnologies Files Prospectus for Resale of 31 Million Shares - Moomoo
CLGN: Selling Stockholders Plan to Offer 31.05 Million Shares - GuruFocus
CollPlant (CLGN) files F-3 to register 31.05M shares from June 2026 PIPE - Stock Titan
CollPlant Biotechnologies Calls July 29 Extraordinary Meeting to Approve Major Share Capital Increase - The Globe and Mail
CollPlant (NASDAQ: CLGN) targets 500M authorized shares in shareholder vote - Stock Titan
CollPlant (Nasdaq: CLGN) raises $2.6M in share and warrant private deal - Stock Titan
CollPlant (CLGN) Secures $2.6 Million in Private Placement Offer - GuruFocus
CollPlant announces $2.6 million private placement By Investing.com - Investing.com Australia
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT - PR Newswire
CollPlant Biotechnologies Ltd. announced that it expects to receive $2.6 million in funding - marketscreener.com
CollPlant Biotechnologies (CLGN) Q4 2025 earnings summary - Quartr
Enterprise value to revenue forward of CollPlant Biotechnologies Ltd. – NASDAQ:CLGN - TradingView
Price to earnings forward of CollPlant Biotechnologies Ltd. – NASDAQ:CLGN - TradingView
Enterprise value to revenue forward of CollPlant Biotechnologies Ltd. – BOATS:CLGN - TradingView
Enterprise value to EBIT forward of CollPlant Biotechnologies Ltd. – NASDAQ:CLGN - TradingView
Price to book forward of CollPlant Biotechnologies Ltd. – NASDAQ:CLGN - TradingView
Price to book forward of CollPlant Biotechnologies Ltd. – BOATS:CLGN - TradingView
Enterprise value to EBITDA forward of CollPlant Biotechnologies Ltd. – BOATS:CLGN - TradingView
Collplant Biotechnologies Ltd (CLGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CollPlant Biotechnologies Ltd Actuals & Estimates (NASDAQ:CLGN) - TradingView
CollPlant Biotechnologies (CLGN) Faces Pressure Near Key SupportKAMA Signal - dars.gov.et
CLGN Technical Analysis & Stock Price Forecast - Intellectia AI
CollPlant Biotechnologies Clings to $0.34 in Low-Volatility ConsolidationRVOL Spike - DonanımHaber
Collplant Biotechnologies Ltd (CLGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Collplant Biotechnologies Ltd (CLGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Collplant Biotechnologies Ltd (CLGN) Institutional Confidence - TradingKey
Collplant Biotechnologies Ltd (CLGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Collplant Biotechnologies Ltd (CLGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Collplant Biotechnologies Ltd (CLGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Collplant Biotechnologies Ltd - TradingKey
CollPlant Heads Toward Nasdaq Deadline With Stock at 40 Cents - Bez Kabli
CollPlant Biotechnologies (CLGN) Holds Near Support Amidst Modest Downside PressureBear Flag - newsline.com
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Sahm
CollPlant Biotechnologies Posts Wider Q1 Loss as It Explores Strategic Alternatives and Advances Regenerative Aesthetics Pipeline - The Globe and Mail
CollPlant Biotechnologies (CLGN) Hovers Near Support at $0.38 After Marginal DeclineSuperTrend Flip - DonanımHaber
Deal Dispatch: Fertitta Entertainment Buys Caesars For $17.6 Billion, Arsenal Capital Buys Velcro Brands, Teaneck Surgical Center Bankruptcy - Benzinga
CollPlant (CLGN) Reports Q1 2026 Financials and Strategic Updates - GuruFocus
CollPlant Q1 revenue falls to $73K, initiates strategic review - grafa.com
Collplant Biotechnologies: No Definitive Timetable for Process >CLGN - Moomoo
Collplant Biotechnologies: Initiates Process to Evaluate Strategic Alternatives Aimed at Maximizing Shareholder Value >CLGN - Moomoo
Collplant Biotechnologies 1Q Loss $3.1M >CLGN - Moomoo
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
CLGNCollPlant Biotechnologies Ltd Stock Price and Quote - Finviz
CollPlant Biotechnologies (CLGN) Slips Slightly as Stock Tests Key Support near $0.40Market Leader Picks - newsline.com
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Quantisnow
CLGN Q4 2025 Earnings: Miss on EPS as Pre-Revenue Biotech Advances PipelineViral Trade Signals - Newser
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
3.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):